The Cold Open
CJC-1295 is the peptide that only needs to be injected once a week. That's its whole pitch: you get sustained, elevated growth-hormone and IGF-1 levels for days from a single shot. It's also the peptide whose clinical development was halted after a Phase II trial participant died of a heart attack. Causality was debated. The program was not resumed. This month: what CJC-1295 does, why it lasts so long, and what actually happened in that halted trial.
Peptide of the Month: CJC-1295
What it is. CJC-1295 is a 30-amino-acid synthetic analog of GHRH, the same hormone Sermorelin is a fragment of. The key difference is a chemical modification called DAC (Drug Affinity Complex). Think of DAC as a grappling hook: it grabs onto serum albumin and rides along for days. That bioconjugation extends CJC-1295's half-life from a few minutes to roughly six to eight days. One weekly injection does the work of daily Sermorelin shots.
What it's supposedly for. Muscle growth, fat loss, better recovery, deeper sleep, anti-aging. Often stacked with Ipamorelin in compounding protocols so both arms of GH release (GHRH receptor and ghrelin receptor) are stimulated together.
The evidence as of today. A 2006 Phase I trial in healthy adults found single SC doses raised mean GH levels 2-to-10-fold for six days, and IGF-1 levels 1.5-to-3-fold for 9 to 11 days. A second 2006 study confirmed pulsatile GH secretion was preserved despite continuous stimulation. A preclinical study in GHRH-knockout mice showed it restored normal growth. These are real, reproducible endocrine effects. That is the full extent of CJC-1295's clinical record.
One thing to know: the halted Phase II. ConjuChem, the developer, ran a Phase II trial in HIV-associated lipodystrophy patients. During the trial, a participant died of a myocardial infarction. Whether the drug caused the event was heavily debated given the cohort's underlying cardiovascular risk, but the program was halted. CJC-1295 was never resumed by a legitimate developer.
A peptide with elegant pharmacology, published Phase I data, and a clinical program that ended with a death and no further development.
The catch. Not FDA-approved. The six-to-eight-day half-life, which is the selling point, is also the risk. If you have an adverse reaction to a daily injection, you stop. If you have an adverse reaction to a weekly injection, you have up to a week of sustained exposure before the drug clears. Elevated IGF-1 for that long is not a trivial exposure profile, especially when long-term safety data in healthy adults doesn't exist.
Skeptic's Corner: Stacking CJC-1295 and Ipamorelin
The most common protocol in wellness clinics pairs CJC-1295 with Ipamorelin. The logic sounds plausible: hit the GHRH arm and the ghrelin arm of GH release simultaneously for a bigger, more natural-looking pulse.
Here's the thing. Two peptides with no successful Phase II efficacy trials, neither FDA-approved, combined in a protocol never tested in a controlled trial. The pharmacologic rationale is real. The outcomes data is nonexistent. You are running the Phase II trial yourself.
The rule: Stacking two peptides does not combine their evidence. It combines their risks. The burden of proof goes up, not down, when you add a second investigational molecule to the first.
Not medical advice. Most peptides discussed in this newsletter are investigational or research chemicals. Talk to a clinician before starting anything.